ConductScience.org, home

Comparison · NCT01019369-110fa664

Self Administration of DMPA vs Clinic Administration of DMPA: Number of Participants Continuing DMPA at 6 Months

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Self Administration of DMPA vs Clinic Administration of DMPA: Number of Participants Continuing DMPA at 6 Months. Trial comparisons, record NCT01019369-110fa664. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01019369-110fa664

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.7090.6060.795wilson
Risk in group 20.6440.4980.768wilson
Risk difference, group 1 minus group 20.0649-0.0960.234newcombe hybrid score
Risk ratio, group 1 over group 21.10.8521.42log
Odds ratio, group 1 over group 21.350.6252.9log
Number needed to treat, for one more participant with the outcome on Self Administration of DMPA than on Clinic Administration of DMPA15.4from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Self Administration of DMPASelf administration of subcutaneous (SC) DMPA (depot medroxyprogesterone acetate)~Medroxyprogesterone 17-Acetate: Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year6186OG000
Group 2Clinic Administration of DMPAClinic administration (routine care) of DMPA~Medroxyprogesterone 17-Acetate: Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year2945OG001

Outcome

Type
PRIMARY
Title
Number of Participants Continuing DMPA at 6 Months
Description
The study was designed to examine if increasing accessibility to DMPA by decreasing the need for multiple clinic visits will increase participant continuation of DMPA
Time frame
6 months
Population
Data was analyzed with the assumption that participants who were lost to follow-up had discontinued DMPA use.

Source ClinicalTrials.gov

Trial

Title
Study of Self or Clinic Administration of DepoProvera
NCT number
NCT01019369
Phases
NA
Conditions
Contraception
Interventions
Medroxyprogesterone 17-Acetate, Medroxyprogesterone 17-Acetate
Lead sponsor
Carolyn L. Westhoff
Results first posted
2015-04-15

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01019369-110fa664